FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, […]

Read More

Cancer and the Holidays: Answers to Common Questions

The holidays can come upon us very quickly, especially if you or a loved one has been dealing with a diagnosis of cancer. Amber Bauer with ASCO has some answers dealing with Cancer and the holidays. Take a few minutes and read some of the great advice on coping with cancer during this hectic time […]

Read More

Important holiday safety advice for cancer patients and families

For many of us, upcoming holidays mean family and friends gathering together and sharing meals in celebration. If someone in your family is undergoing treatment for cancer, keep in mind these few precautions for their continued health and safety. Chemotherapy can knock out the body’s white blood cell count making it very vulnerable to germs. […]

Read More